Affymax (AFFY) Announces Another Data Monitoring Committee Review of Phase 3 Hematide Program
More News related to AFFY
- Affymax to Present at Piper Jaffray 21st Annual Healthcare Conference
- Affymax (AFFY) Closes Stock Offering, Receiving Net Proceeds of $80M
- Affymax Announces Close of Common Stock Offering and Exercise of Underwriters' Overallotment Option
- Affymax (AFFY) Prices 4.1M Shares at $18.25/Share
- Affymax Prices Public Offering of Common Stock
More News related to FDA
- Steris (STE) Sinks After FDA Notice on Concerns About the Steris System 1 Processor
- Watson Pharmaceuticals (WPI) Files New Drug Application with FDA for Generic Rozerem
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
- Somaxon (SOMX) Volatile Into FDA Action Date
Affymax, Inc. (Nasdaq: AFFY) announced that the independent Data Monitoring Committee, which provides oversight for the Phase 3 program for Hematide(TM), has completed another review and has informed the company that the cumulative safety data generated thus far from the EMERALD and PEARL Phase 3 trials support continuation of the studies. In the Phase 3 program, Hematide is being evaluated to treat anemia in chronic renal failure patients on dialysis and not on dialysis.
The Phase 3 program, which consists of four trials, was initiated in October 2007. Affymax announced that enrollment was complete in all four Phase 3 trials in November 2008 and reiterated its expectation for a NDA submission in 2010.
Related Categories
FDAStocks Mentioned
+0.30Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
